Jun DW, Kim BI, Cho YK, Kim HJ, Kwon YO, Park SY, Han SY, Baek YH, Jung YJ, Kim HY, Kim W, Heo J, Woo HY, Hwang SG, Rim KS, Choi JY, Bae SH, Lee YS, Lim YS,Cheong JY, Cho SW, Lee BS, Kim SH, Sohn JH, Kim TY, Paik YH, Kim JK, Lee KS
26 HsiehM
[2] The primary side effects documented in clinical trials predominantly involve gastrointestinal symptoms, including nausea, vomiting, diarrhoea, and constipation
Prescribers seeking evidence-based guidance on the neuropsychiatric or affective side effect profile of GLP-1 receptor agonists, including semaglutide, should refer to the published regulatory safety communications from the FDA and EMA, the SUSTAIN and STEP trial data, and peer-reviewed pharmacovigilance literature examining anhedonia, mood changes, and related adverse events in this drug class
Pendulum Therapeutics Introduces GLP-1 Probiotic News provided by Pendulum Therapeutics Mar 13, 2024, 12:00 ET GLP-1 Probiotic is a powerful, effective, and science-backed tool to help naturally boost GLP-1 production and naturally help maintain a healthy weight* SAN FRANCISCO, March 13, 2024 /PRNewswire/ -- Pendulum Therapeutics , a female-led biotech company pioneering the next frontier of metabolic health through its microbiome-targeted products, announces the launch of their GLP-1 Probiotic
Melanocortin System Research: Supports studies on receptor subtype signaling (MC1RMC5R) and neuroendocrine regulation